Novartis: Lung Neoplasms trials
The registry lists 40 Lung Neoplasms studies with Novartis as lead sponsor. 1 are open to participants now and 14 have results posted.
Phase 1 13Phase 2 16Phase 3 5Phase 4 4No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 4
- Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.Active, not recruitingNCT05445843Phase 2Results posted
- Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
- LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
- Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
- Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedNCT01828112Phase 3Results posted
- LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedNCT01828099Phase 3Results posted
- LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerCompletedNCT01685138Phase 2Results posted
- An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsTerminatedNCT01646125Phase 2Results posted
- A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
- Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the PancreasCompletedNCT01433263Phase 2Results posted
- RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4Results posted
- Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung CancerCompletedNCT00171834Phase 1/2Results posted
- A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersTerminatedNCT06376253Phase 1
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaActive, not recruitingNCT05703516
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerTerminatedNCT05132075Phase 3
- Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingNCT04699188Phase 1/2
- Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
- A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
- Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
- A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
- Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
- Study of CLR457 Administered Orally in Adult Patients With Advanced Solid MalignanciesTerminatedNCT02189174Phase 1
- A Dose Escalation Study in Adult Patients With Advanced Solid MalignanciesCompletedNCT01004224Phase 1
- Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural MesotheliomaCompletedNCT00535951Phase 1
- Safety of Everolimus and Pemetrexed in Lung Cancer PatientsCompletedNCT00434174Phase 1
- Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung CancerCompletedNCT00219297Phase 2
- Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
- Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00124280Phase 2
- Non-small Cell Lung Cancer RegistryCompletedNCT00099541Phase 4
- Non-small Cell Lung Cancer Study US75 (Z-PACT)CompletedNCT00086268Phase 3
- Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast CancerCompletedNCT00006370Phase 2
- Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
- Zoledronate in Treating Patients With Solid Tumors That Have Spread to the BoneCompletedNCT00003884Phase 3